Skip to search formSkip to main contentSkip to account menu

BT 563

Known as: BT-563, BT563 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

inolimomab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
2004
2004
Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor.
1998
1998
A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
The introduction of quadruple induction therapy after liver transplantation with the murine anti-interleukin-2 receptor (IL-2R… 
1998
1998
Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans.
BACKGROUND Anti-interleukin (IL)-2 receptor (IL-2R) antibodies have been used as rejection prophylaxis after organ… 
1998
1998
Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.
Highly Cited
1997
Highly Cited
1997
A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver…
BACKGROUND Quadruple immunosuppressive induction therapy has been shown to markedly reduce the incidence of acute rejection… 
Highly Cited
1996
Highly Cited
1996
Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.
The immunosuppressive effect of a monoclonal antibody (moAb), BT563, directed to the alpha-chain of the IL-2R (CD25), was… 
1996
1996
A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation.
In a prospective randomized trial, BT563, a murine IgG, anti-interleukin-2 receptor antibody, was compared with OKT3 for use as… 
Highly Cited
1995
Highly Cited
1995
TREATMENT OF ACUTE GRAFT‐VERSUS-HOST DISEASE WITH METHYLPREDNISOLONE AND CYCLOSPORINE WITH OR WITHOUT AN ANTI‐INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY: A Multicenter Phase III Study
A double-blind, placebo-controlled trial of BT563, including 13 European centers, was initiated in October 1989 to compare the… 
1995
1995
Pharmacodynamics of prophylactic antirejection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation.
A mouse monoclonal antibody (BT563) directed to the alpha-chain of the IL-2 receptor was administrated immediately after… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)